The site does not offer professional or financial advice. The opinions expressed here are based on the writer’s opinion, research and personal experience, and they should not be taken as facts. The information on this site is general in nature and does not cater to specific individuals or entities.
In this bear market, it is an uphill task for small and mid-cap stocks to remain relevant. While many stocks got hit hard, some have bucked the trend. One such stock that has emerged as a winner in this turbulent period is Athira Pharma. The company has outperformed its peers by a large margin.
You’ve heard all kinds of views on the stock market, some good and some bad. Even as there are risks around investing in stocks — what if you invest and the stock falls? — investors have been flocking to them for their potential for big rewards. As with any investment, it’s essential to do your research before diving in.
However, you can still find great opportunities out there waiting for investors to discover them, so let’s look at one such option. This article will look closely at Athira Pharma’s stock, business model, and future growth potential.
NASDAQ: ATHA Overview
Athira Pharma is a global healthcare company that develops and manufactures dosage forms and finished dosage products. Its developments include oral, injectable, and biotechnology products, such as vaccines and blood products. The company operates in four segments — Specialty Pharma, Biologics, Dosage Form Operations, and Contract Manufacturing.
This company’s Specialty Pharma segment offers specialty injectable drugs and vaccines, including the Epaxal Injection (for treating refractory angioedema) and the Guanflu Human Papillomavirus Vaccine (for the prevention of cervical cancer and genital warts). Athira has been in the industry since 2002 and has a presence in the US, India, China, and Europe.
Furthermore, it is a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases. The company’s lead product candidate, ATHA-119, is in clinical development to treat Alzheimer’s disease.
It started working in 2015 with headquarters in San Diego, California. Moreover, the company aims to develop innovative therapies that restore brain function and improve patients’ lives with neurodegenerative diseases.
NASDAQ: ATHA Stock Forecast 2022
Athira shares have been in a strong uptrend since the beginning of the calendar year and have made significant gains. Given the stock’s high valuation, it can drop a few percentage points soon before starting a new uptrend. We expect the stock to trade between $2 and $5 in 2022 as investors wait for a correction in the stock.
The stock currently trades at around $2.99, more than 50% lower than its price at the end of last year. This fall means it’s time to buy, which would be a good investment opportunity for long-term investors. Athira Pharma stock might offer a potential annualized return of around 36% based on the current price.
NASDAQ: ATHA Stock Forecast 2023
In 2023, we expect Athira to thrive, driven by rising disposable income and to improve healthcare standards in emerging markets. Next year, we anticipate the stock to trade between $7-$12, which would triple its share price from its current levels.
The company’s long-term growth potential makes Athira an excellent long-term investment. Investors looking for a long-term payoff can buy the stock at current levels and hold it for at least five years. Given the strong growth potential, Athira can deliver better returns in 2023.
Athira Pharma Inc. has received a $12.00 price target from research analysts’ reports issued to clients and investors. It presently has an “overweight” rating on the stock, and the target price would suggest a potential upside of 92.31% from the company’s current price.
Several other research analysts have also weighed in on ATHA. In a research report, some lowered Athira Pharma’s shares from “buy” to a “hold” rating. Others started coverage of Athira Pharma in a research report and set a “buy” rating and a $10.00 price target on the stock.
Finally, some reports reaffirmed a “buy” rating on shares of Athira Pharma with a hold rating. The company presently has an average rating of “Buy” and an average target price of $10.
NASDAQ: ATHA Stock Forecast 2024
At Athira Pharma stock’s current valuation, the stock has a value of around $15-$20. Although the stock is trading at a reasonable valuation currently, it has strong growth potential in the long term.
We expect the company to benefit from rising disposable income, improving healthcare standards, and an expanding middle class. Therefore, the stock can provide a long-term annualized growth rate over the next five years.
Athira Pharma Inc. has received a price target increase from $10 to $15 from several reports. This new price target represents a potential upside from the stock’s current price.
Analysts are raising their PT to $15 from $10 as they see Athira’s Alzheimer’s program derisking and the company becoming an acquisition target. With the recent data readout from Part 1 of the ongoing Phase 1b/2a study of ATH-1017 in patients with mild-to-moderate Alzheimer’s disease, they see the program derisking.
The data showed that ATH-1017 was well tolerated, with no serious adverse events or cognitive decline. These data increase the probability of success in the ongoing Phase 2b study. Furthermore, the analysts concluded that with a derisked Alzheimer’s program and a market cap of only ~$300M, they believe Athira is an attractive acquisition target.
NASDAQ: ATHA Stock Forecast 2025
At Athira’s current valuation, the stock is reasonably valued and can trade between $15-$25 in 2025. Athira is an excellent long-term investment with solid growth potential. The company is expanding aggressively in the global market, and it is also diversifying its product portfolio.
Athira Pharma has received a price target of $20 from analysts based on the company’s strong performance in the past year.
The company’s products are in high demand, and its innovative research and development have resulted in several new products being well-received in the market.
ATHA’s strong financial performance may continue in the future, and the company is well-positioned to take advantage of the growing demand for its products. Analysts believe that ATHA’s stock is undervalued at its current price and expect it to reach $20 in 2025.
Long-Term Forecast 2030
If you research and make intelligent decisions, investing in stocks can be very profitable over the long term. Let’s look at one such investment, the Athira Pharma stock. We forecast Athira Pharma’s long-term earnings growth rate, which is significantly above the average for the broader healthcare sector. What’s driving this forecast? It’s the company’s strong focus on emerging markets.
Athira Pharma has received a price target of $24.00 from research analysts in a recent report. The firm presently has an “outperform” rating on the stock. Moreover, the analyst’s price objective would indicate a potential upside of 38.46% from the company’s previous close.
ATHA has been the subject of several recent research reports. Several other research firms have also issued reports on ATHA.
Zacks research cut shares of Athira Pharma from a “buy” rating to a “hold” rating in a research note on Friday, March 5th. ValuEngine cut shares of Athira Pharma from a “hold” rating to a “sell” rating in a research note on Friday, February 12th. Finally, HC Wainwright reissued a “buy” rating on shares of Athira Pharma in a research note on Thursday, February 11th.
NASDAQ: ATHA Price Analysis
Before deciding whether or not to buy NASDAQ: ATHA, check its valuation. The valuation will tell you how inexpensive or expensive the company is relative to its peers, which is helpful because sometimes stocks snowballing, like Athira Pharma, can be costly.
Let’s see what Athira Pharma’s price analysis looks like now. Athira Pharma is currently trading at a price-to-earnings ratio of 19.8 times its expected earnings in the next 12 months.
While this ratio is slightly above the broader healthcare sector average of 19.3 times earnings, it’s below the sector average of 22.4 times earnings. Furthermore, the company trades at a discount to many of its peers, making it ideal for investing.
NASDAQ: ATHA Prediction Conclusion
Athira Pharma is a global healthcare company that develops and manufactures dosage forms and finished dosage products. The company has a wide range of products, including specialty injectable drugs, vaccines, and blood products.
ATHA has been in the industry for over a decade and is expanding aggressively in the global market. Given the solid and lucrative long-term growth potential, this stock is an attractive long-term buy.
Athira Pharma is one of the most promising stocks in the market right now. Its innovative products and cutting-edge technology make it an excellent choice for investors. The company might continue to grow rapidly, and its stock price may rise in the future.
There’s plenty of data to analyze when examining market forecasts for a stock. Since we want to be a helpful resource for investors looking for information, we’ve included this FAQ section to help you quickly find answers to common questions. If you have any concerns about what you’ve just read or about the ATHA stock, please read the following frequently asked questions:
What Is NASDAQ: ATHA’s Financials
The company’s net sales grew by around 26% YoY in FY19, driven by an increase in revenues from the company’s Specialty Pharma and Biologics segments. Specialty Pharma revenues rose by 34% YoY, while Biologics revenues increased by around 7% YoY.
An increase in customers’ prescriptions also supported the company’s sales growth. Athira’s launch of new products drove this, and its net sales may grow from the current level to $650 million by the end of FY22.
The company’s operating margin for FY19 was around 11.9%, which is about 1.3% lower than the previous year. This drop in operating margin was due to increased spending on research and development activities.
NASDAQ: ATHA Stock Return Potential: Is It a Good Time to Buy?
Its strong growth potential, solid financials, and lucrative long-term growth possibility make Athira Pharma stock an attractive long-term investment opportunity. At Athira’s current valuation of $2.99, the stock has a price-to-earnings ratio of around 16. This ratio is about 5% lower than Athira’s five-year average price-to-earnings ratio of 17.
Given Athira’s strong growth potential, the stock has a value with a golden price-to-earnings ratio. Furthermore, the stock currently yields around 2.5% and has a dividend payout ratio of about 24%. Because of its growth potential, the stock may generate above-average returns in the long term. Therefore, Athira is best suited for investors looking for a long-term investment.
Why Should You Care about NASDAQ: ATHA?
Athira Pharma is a fast-growing company in an attractive industry. It boasts a strong focus on the rapidly developing markets of Asia, South America, and Africa, where many people cannot afford more expensive drugs.
Moreover, the company’s strong balance sheet gives it the necessary resources to grow even more. As a result, its revenue and profit increased rapidly. Even though its stock is currently trading above its average price-to-earnings ratio, it’s still significantly below its five-year average.
What Are the Benefits of Investing in Athira Pharma
Athira Pharma is a pharmaceutical company dedicated to developing new treatments for Alzheimer’s and other neurological disorders. The company is currently in clinical trials for its lead compound, ATH-1017, a novel small molecule that can potentially reduce the production of amyloid beta. This protein might be the leading cause of Alzheimer’s disease.
Investing in Athira Pharma could be a wise decision for several reasons. First, the company’s lead compound, ATH-1017, is currently in clinical trials and showing promising results. If the FDA approves the compound, it could be a game-changer for treating Alzheimer’s.
Additionally, the company has a solid intellectual property portfolio, with over 40 patents and pending applications. Finally, Athira Pharma has a team of experienced executives and scientists with a proven track record in the pharmaceutical industry.
Athira is a company that is worth watching. If its lead compound, ATH-1017, is approved by the FDA, it could be a breakthrough in treating Alzheimer’s disease and increasing its ATHA stock.
Finally, ATHA is the best choice if you’re looking for a stock that’s on discount and grows rapidly over time. One of the most remarkable things about this stock and company is that it develops a compound that helps people with diseases, which may increase the stock’s price if the FDA approves it.
StockHax strives to provide unbiased and reliable information on cryptocurrency, finance, trading, and stocks. However, we cannot provide financial advice and urge users to do their own research and due diligence.Read More